Can a shorter radiation course tame side effects in head and neck cancer?

NCT ID NCT01211938

First seen Aug 17, 2026 ยท Last updated Aug 17, 2026

Summary

This trial is testing two different ways of delivering a second course of radiation to people whose head or neck cancer has come back after prior radiation. One approach uses a single daily dose of radiation combined with two chemotherapy drugs given every other week over 11 weeks. The other uses a more frequent, smaller-dose radiation schedule combined with a targeted therapy called cetuximab over 5 weeks. The goal is to see which approach causes fewer severe side effects and whether either helps control the cancer longer.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
radiation therapy (single-fraction with 5FU and Hydrea, or hyperfractionated with cetuximab)
What this could lead to
If successful, this could identify a safer way to deliver a second course of radiation to people with recurrent head and neck cancer, potentially improving their quality of life and survival.
What could go wrong
This is an early-stage trial with a small number of patients, so results may not apply broadly. Reirradiation carries risks of severe side effects, and the added drugs (5FU, Hydrea, cetuximab) can cause their own toxicities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut Gustave Roussy

    Villejuif, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.